Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Part of paid clinical trials in Stanford, California.

Sponsor
Ranjana Advani
Study ID
NCT04788043
Phase
PHASE2
Status
Terminated

Conditions

  • Classic Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma
  • Relapsed Classical Hodgkin Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Magrolimab — DRUG
    45 mg/kg with dose escalation starting at 1 mg/kg IV Infusion
  • Pembrolizumab — DRUG
    200 mg IV infusion
  • PET/CT — PROCEDURE
    Scan

Study Details

The purpose of this study is to test the safety and efficacy of magrolimab in combination with pembrolizumab in patients with Hodgkin lymphoma.

Key Dates

Start date
Jun 21, 2022
Status verified
Jun 2026
Primary completion
Oct 11, 2024
Completion
Aug 29, 2025

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Magrolimab (Hu5F9 G4) and pembrolizumab
    All subjects will have a baseline PET CT and excisional or core needle biopsy within 1 month of study enrollment and baseline electrocardiogram and laboratory studies within 1 week of study enrollment. All subjects will receive treatment with magrolimab and pembrolizumab according to the dosing schedule. Magrolimab IV given on cycle 1, 2 and 3. Pembrolizumab 200 mg IV given on Cycle 1, 2 and 3. Patients may continue to receive treatment on the study for a maximum of 24 months or until progression of disease, unacceptable toxicity, or bridge to stem cell transplantation (SCT).

Primary Outcome Measure

Complete Response (CR) [ Time Frame: Up to 2 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
Stanford UniversityStanfordCalifornia94304-
Dana Farber Cancer InstituteBostonMassachusetts02215-

Related coverage on Hipa.ai

Find similar trials in Stanford, CA

By research site
Stanford University· Stanford, CADana Farber Cancer Institute· Boston, MA

Related Studies